A
Alcista
Alcista · 25%SRRK
$56.96
Precio del escenario
$39.900
-0.726 (-1.82%)Al cierre
Loading chart…
- Máximo
- 41.280
- Apertura
- 40.610
- Precio medio ponderado por volumen
- 39.96
- Volumen
- 2.89M
- Capitalización
- 666.74M
- Mínimo
- 38.690
- Importe
- 115.64M
- EV/EBITDA, TTM
- 0.00
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Análisis de IA of Scholar Rock Holding Corp (SRRK)
MantenerScholar Rock Holding Corp (SRRK) is currently not a strong buy due to its recent price decline and negative financial indicators. The current price is $39.90, with a 5-day change of -5.43% and a 20-day change of -14.47%. The RSI is at 24.002, indicating it is in oversold territory, which could suggest a potential rebound. However, the company has reported significant net losses, with a net income of -$109,896,000 in Q2 2026, and a forward P/E ratio of 0, indicating no earnings expectations. The main risk is the ongoing negative sentiment reflected in the stock's recent performance and the uncertainty around the uptake of its newly approved drug, ISEMBYLD, which has a market reaction that remains cautious. Therefore, while there are positive catalysts like FDA approval, the financial health and current price trends suggest holding off on new purchases for now.
Recomendaciones de analistas (4)
+25.31% de potencial alcista
Comprar
4 Comprar
0 Mantener
0 Vender
Actual: 39.90
Mínimo
42.00
Promedio
50.00
Máximo
60.00
Wedbush
Superar al mercado
—
2026-09-25
Wedbush
2026-09-25
Precio objetivo
—
Superar al mercado
Truist
Comprar
$77
2026-09-24
Truist
2026-09-24
Precio objetivo
$77
Comprar
JPMorgan
Sobreponderar
$70
2026-09-21
JPMorgan
2026-09-21
Precio objetivo
$70
Sobreponderar
Evercore ISI
Superar al mercado
$72
2026-09-15
Evercore ISI
2026-09-15
Precio objetivo
$72
Superar al mercado
Piper Sandler
Sobreponderar
$75
2026-09-15
Piper Sandler
2026-09-15
Precio objetivo
$75
Sobreponderar
Métricas de valoración
El PER previsto actual de Scholar Rock Holding Corp (SRRK) es 0.00, frente a su media de 5 años de -7.05.
Escenarios de precio de Alphio AI para SRRK
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con SRRK en cartera
Cronología de eventos
Noticias
8.510-08NewsfilterScholar Rock Resubmits Apitegromab MAA with New Facility
7.009-30PRnewswireKuehn Law Investigates Scholar Rock Executives for Fiduciary Breach
9.009-28stocktwitsFDA Decisions Loom for Bristol Myers and Others
- 5.009-21Newsfilter
Scholar Rock Grants Inducement Equity Awards to New Employees
- 8.509-15Newsfilter
Scholarock Secures FDA Approval for First Muscle-Targeted Therapy
Preguntas frecuentes sobre SRRK, respondidas por Alphio AI
Scholar Rock Holding Corporation is a biopharmaceutical company. The Company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe and debilitating neuromuscular diseases. Its pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439. The Apitegromab is an investigational fully human, intravenously administered monoclonal antibody designed to inhibit myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. The SRK-439, is an investigational, subcutaneously administered fully human anti-pro/latent myostatin antibody that has high inhibitory potency while maintaining selectivity towards myostatin. Its early-stage pipeline includes additional programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
Scholar Rock Holding Corp (SRRK) is currently not a strong buy due to its recent price decline and negative financial indicators. The current price is $39.90, with a 5-day change of -5.43% and a 20-day change of -14.47%. The RSI is at 24.002, indicating it is in oversold territory, which could suggest a potential rebound. However, the company has reported significant net losses, with a net income of -$109,896,000 in Q2 2026, and a forward P/E ratio of 0, indicating no earnings expectations. The main risk is the ongoing negative sentiment reflected in the stock's recent performance and the uncertainty around the uptake of its newly approved drug, ISEMBYLD, which has a market reaction that remains cautious. Therefore, while there are positive catalysts like FDA approval, the financial health and current price trends suggest holding off on new purchases for now.
4 analysts cover SRRK: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 50.00.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.